抗病毒治疗的重要性和必要性剖析.ppt

* * * * * * * * * * * * * * * * * * * * * * * * * * ETV在2005年3月29日在美国获FDA批准上市，2005年11月获SFDA批准，2006年2月在中国正式上市。 * * * * ADV, adefovir; ETV, entecavir; LAM, lamivudine, LdT, telbivudine; L-FMAU, clevudine; TDF, tenofovir. This slide demonstrates the HBV?DNA reduction with oral agents in HBeAg–positive patients with chronic hepatitis?B. A word of caution is that these data are from individual reports and do not represent direct comparisons, but you can see a general sense of the variable potency of the different agents. The least potent agent is adefovir, on the left, with a 3.5 log reduction at t